Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage

Pinar Karaca-Mandic, Jessica Chang, Ronald Go, Stephen Schondelmeyer, Daniel Weisdorf, Molly Moore Jeffery

Research output: Contribution to journalArticle


In 2015 the Food and Drug Administration approved filgrastim-sndz (Zarxio), the first US biosimilar. Following rapid uptake, by March 2018 filgrastim-sndz accounted for 47 percent of filgrastim administrations among commercially insured and 42 percent among Medicare Advantage beneficiaries. The initial cost difference between the originator and biosimilar was 31 percent in the former population but negligible in the latter.

Original languageEnglish (US)
Pages (from-to)1887-1892
Number of pages6
JournalHealth affairs (Project Hope)
Issue number11
StatePublished - Nov 1 2019


  • Biologics
  • Biosimilar
  • Biosimilars
  • Cost reduction
  • FDA approvals process
  • Filgrastim-sndz
  • Health policy
  • Medicare Advantage
  • Out-of-pocket expenses
  • Pharmaceuticals
  • Prescription drug costs
  • Zarxio

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Biosimilar Filgrastim Uptake And Costs Among Commercially Insured, Medicare Advantage'. Together they form a unique fingerprint.

  • Cite this